Advertisement

Molecular Diagnosis & Therapy

, Volume 17, Issue 1, pp 57–62 | Cite as

Erlotinib

A Guide to Its Use in First-Line Treatment of Non-Small-Cell Lung Cancer with Epidermal Growth Factor-Activating Mutations
  • Katherine A. Lyseng-WilliamsonEmail author
Adis Drug Clinical Q&A

Abstract

In the EU, the approved use of erlotinib (Tarceva®), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has recently been expanded to include first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in patients with EGFR-activating mutations. In randomized, open-label, phase III clinical trials, oral erlotinib reduced the risk of progression, improved response rates, and was well tolerated relative to standard platinum-based doublet chemotherapy in Caucasian and Asian populations with advanced NSCLC with EGFR-activating mutations.

Keywords

Epidermal Growth Factor Receptor Gefitinib Erlotinib National Comprehensive Cancer Network Epidermal Growth Factor Receptor Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were by the author on the basis of scientific and editorial merit.

References

  1. 1.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.PubMedCrossRefGoogle Scholar
  2. 2.
    D’Addario G, Früh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v116–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Leighl NB. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol. 2012;19(Suppl 1):S52–8.PubMedGoogle Scholar
  4. 4.
    Triano LR, Deshpande H, Gettinger SN. Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs. 2010;70(2):167–79.PubMedCrossRefGoogle Scholar
  5. 5.
    Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer. 2012;13(2):107–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Langer CJ. Roles of EGFR and KRAS mutations in the treatment of patients with non-small-cell lung cancer. P T. 2011;36(5):263–79.PubMedGoogle Scholar
  7. 7.
    National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology (NCCN guidelines®): non-small cell lung cancer. Version 3.2012. Fort Washington: National Comprehensive Cancer Network; 2012.Google Scholar
  8. 8.
    Paz-Ares L, Soulieres D, Melezinek I, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med. 2010;14(1–2):51–69.PubMedCrossRefGoogle Scholar
  9. 9.
    Tarceva (erlotinib) film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2012.Google Scholar
  10. 10.
    Hidalgo M, Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin Oncol. 2003;30(3 Suppl 7):25–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Kamel-Reid S, Chong G, Ionescu DN, et al. EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer. Curr Oncol. 2012;19(2):e67–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Ling YH, Li T, Yuan Z, et al. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol. 2007;72(2):248–58.PubMedCrossRefGoogle Scholar
  13. 13.
    Ling YH, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptor L858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol. 2008;74(3):793–806.PubMedCrossRefGoogle Scholar
  14. 14.
    Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs. 2004;15(5):503–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.PubMedCrossRefGoogle Scholar
  16. 16.
    Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15(16):5267–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.PubMedCrossRefGoogle Scholar
  18. 18.
    Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhou C, Wu YL, Liu X, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC) [abstract no. 7520]. J Clin Oncol. 2012;30(15 Suppl):7520.Google Scholar
  20. 20.
    National Institute for Health and Clinical Excellence. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer: NICE technology appraisal guidance 258. London: National Institute for Health and Clinical Excellence; 2012.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations